These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15032654)

  • 1. Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension.
    Susic D; Varagic J; Ahn J; Frohlich ED
    Curr Drug Targets Cardiovasc Haematol Disord; 2004 Mar; 4(1):97-101. PubMed ID: 15032654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosslink breakers: a new approach to cardiovascular therapy.
    Susic D; Varagic J; Ahn J; Frohlich ED
    Curr Opin Cardiol; 2004 Jul; 19(4):336-40. PubMed ID: 15218393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
    Bakris GL; Bank AJ; Kass DA; Neutel JM; Preston RA; Oparil S
    Am J Hypertens; 2004 Dec; 17(12 Pt 2):23S-30S. PubMed ID: 15607432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes.
    Aronson D
    J Hypertens; 2003 Jan; 21(1):3-12. PubMed ID: 12544424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-link breakers as a new therapeutic approach to cardiovascular disease.
    Susic D
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):853-6. PubMed ID: 17956231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys.
    Vaitkevicius PV; Lane M; Spurgeon H; Ingram DK; Roth GS; Egan JJ; Vasan S; Wagle DR; Ulrich P; Brines M; Wuerth JP; Cerami A; Lakatta EG
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1171-5. PubMed ID: 11158613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines.
    Shapiro BP; Owan TE; Mohammed SF; Meyer DM; Mills LD; Schalkwijk CG; Redfield MM
    Circulation; 2008 Sep; 118(10):1002-10. PubMed ID: 18711013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats.
    Chan V; Hoey A; Brown L
    Br J Pharmacol; 2006 Aug; 148(7):902-8. PubMed ID: 16783413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.
    Zieman SJ; Melenovsky V; Clattenburg L; Corretti MC; Capriotti A; Gerstenblith G; Kass DA
    J Hypertens; 2007 Mar; 25(3):577-83. PubMed ID: 17278974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart.
    Liu J; Masurekar MR; Vatner DE; Jyothirmayi GN; Regan TJ; Vatner SF; Meggs LG; Malhotra A
    Am J Physiol Heart Circ Physiol; 2003 Dec; 285(6):H2587-91. PubMed ID: 12946933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of arterial stiffening: role of glycation - a mini-review.
    Sell DR; Monnier VM
    Gerontology; 2012; 58(3):227-37. PubMed ID: 22222677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms.
    Nichols WW
    Am J Hypertens; 2005 Jan; 18(1 Pt 2):3S-10S. PubMed ID: 15683725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders.
    Yamagishi S
    Rejuvenation Res; 2012 Dec; 15(6):564-72. PubMed ID: 22950433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease.
    Zieman SJ; Kass DA
    Drugs; 2004; 64(5):459-70. PubMed ID: 14977384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease.
    Zieman S; Kass D
    Congest Heart Fail; 2004; 10(3):144-9; quiz 150-1. PubMed ID: 15184729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats.
    Badenhorst D; Maseko M; Tsotetsi OJ; Naidoo A; Brooksbank R; Norton GR; Woodiwiss AJ
    Cardiovasc Res; 2003 Mar; 57(3):632-41. PubMed ID: 12618225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial stiffness and left ventricular diastolic function in the patients with hypertension.
    Agoşton-Coldea L; Mocan T; Bobar C
    Rom J Intern Med; 2008; 46(4):313-21. PubMed ID: 19480297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALT-711 decreases cardiovascular stiffness and has potential in diabetes, hypertension and heart failure.
    Doggrell SA
    Expert Opin Investig Drugs; 2001 May; 10(5):981-3. PubMed ID: 11424901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications.
    Benetos A; Waeber B; Izzo J; Mitchell G; Resnick L; Asmar R; Safar M
    Am J Hypertens; 2002 Dec; 15(12):1101-8. PubMed ID: 12460708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats.
    Norton GR; Candy G; Woodiwiss AJ
    Circulation; 1996 May; 93(10):1905-12. PubMed ID: 8635270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.